Pharmacoeconomics of medical abortion: A review of cost in the United States, Europe and Asia

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 4, 2003, Pages 503-513

  Murthy, Amitasrigowri ^a   Creinin, Mitchell D ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost; Economics of abortion; Medical abortion; Mifepristone; Misoprostol; Surgical abortion

Indexed keywords

ANTIBIOTIC AGENT; ANTIGESTAGEN; GEMEPROST; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; METHOTREXATE; MIFEPRISTONE; MISOPROSTOL; PROGESTERONE RECEPTOR; PROSTAGLANDIN DERIVATIVE; SULPROSTONE;

AREA UNDER THE CURVE; ASIA; CHILL; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG COST; EUROPE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEART DISEASE; HUMAN; INDUCED ABORTION; INTERMETHOD COMPARISON; MONOTHERAPY; PREGNANCY RATE; RECEPTOR BLOCKING; REVIEW; SIDE EFFECT; UNITED STATES;

ABORTION, INDUCED; ADOLESCENT; ADULT; ASIA; COSTS AND COST ANALYSIS; ECONOMICS, PHARMACEUTICAL; EUROPE; EXPERT TESTIMONY; FEMALE; HUMANS; METHOTREXATE; MIFEPRISTONE; MISOPROSTOL; PREGNANCY; UNITED STATES;

EID: 0037397492     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.4.503     Document Type: Review

References (62)

1. CREININ MD: Medical abortion regimens: historical context and overview. Am. J. Obstet. Gynecol, (2000) 183:S3-S9.
2. Facts in Brief induced abortion. The Alan Guttmacher Institute, NY, USA (2003).
3. Fulfilling the promise: public policy and U.S. family planning clinics. The Alan Guttmacher Institute, NY, USA (2000).
4. JONES RK, DARROCH JE, HENSHAW SK: Contraceptive use among US women having abortions in 2000 - 2001. Perspect. Sex. Reproduct. Health (2002) 34(6):294-303.
5. The reproductive rights and health of women of color. National Abortion and Reproductive Rights Action League, Washington DC, USA (2001).
6. HENSHAW SY: Freestanding abortion clinics: services, structure, fees. Fam. Plan. Perspect. (1982) 14(5):248-256.
7. SCHINDLER AM, ZANON P, OBRADOVIC D, WYSS R, GRAFF P, HERMANN WL: Early ultrastructural changes in RU-486 exposed decidua. Gynecol. Obstet. Invest. (1985) 20:62-67.
8. CHRISTIN-MAITRE S, BOUCHARD P, SPITZ IM: Medical termination of pregnancy. New Engl. J. Med. (2000) 342(13):946-956.
9. KELLY RW, HEALY DL, CAMERON MJ, CAMERON IT, BAIRD DT: RU-486 stimulation of PGF-2 production in isolated endometrial cells in short term culture. In: The antiprogestin steroid R U-486 and human fertility control. Baulieu EE, Siegel S (Eds), Plenum Publishers, NY, USA (1985):259-262.
10. PYMAR HC, CREININ MD, SCHWARTZ JL: Mifepristone followed on the same day by vaginal misoprostol for early abortion. Contraception (2001) 64:87-92.
11. CAMERON IT, MICHIE AF, BAIRD DT: Therapeutic abortion in early pregnancy with antiprogestogen RU-486 alone or in combination with prostaglandin analogue (gemeprost). Contraception (1986) 34(5):459-467.
12. ULMANN A, SILVESTRE L, CHEMAMA L, REZVANI Y, RENAULT M, AGUILLAUME CJ: Medical termination of early pregnancy with mifepristone (RU-486) followed by a prostaglandin analogue. Study in 16,369 women. Acta Obstet. Gynecol Scand. (1992) 71:278-283.
13. BAIRD DT SUKCHAROEN N, THONG KJ: Randomized trial of misoprostol and cervagern in combination with a reduced dose of mifepristone for induction of abortion. Hum. Reprod. (1995) 10:1521-1527.
14. AUBÉNY E, BAULIEU ÉÉ: Activité contragestive de l'association au RU-486 d'une prostaglandine activé par voie orale. CR Acad. Sci. III. (1991) 312:539-545.
15. NORMAN JE, THONG KJ, BAIRD DT: Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet (1991) 338:1233-1236.
16. PEYRON R, AUBÉNY E, TARGOSZ V et al: Early termination of pregnancy with mifepristone (RU-486) and the orally active prostaglandin misoprostol. N. Engl. J. Med. (1993) 328:1509-1513.
17. SPITZ IM, BARDIN CW, BENTON L, ROBBINS A: Early pregnancy termination with mifepristone and misoprostol in the United States. N. Engl. J. Med. (1998) 338:1241-1247.
18. AUBÉNY E, PEYRON R, TUPRIN CL et al: Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol. Int. J. Fertil. Menopaus. Stud. (1995) 40(Suppl. 2):S85-S91.
19. EL-RAFAEY H, PENNEY G, FLETT G, TEMPLETON A: Induction of abortion with mifepristone (RU-486) and oral or vaginal misoprostol. N. Engl. J. Med. (1995) 332:983-987.
20. MCKINLEY C, THONG KJ, BAIRD DT: The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum. Reprod. (1993) 8:1502-1505.
21. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomized trial. WHO task force on post-ovulatory methods of fertility Regulation. Br. J. Obstet. Gynaecol. (2000) 107:524-530.
22. WIEBE ER, DUNN S, GUILBERT E, JACOT F, LUGTIG L, WINIKOFF B: Comparison of abortions induced by the methotrexate or mifepristone followed by misoprostol. Obstet. Gynecol. (2002) 99:813-819.
23. DELOIA JA, STEWART-AKERS AM, CREININ MD: Effects of methotrexate effects on trophoblast proliferation and local immune responses. Hum. Reprod. (1998) 13:1063-1069.
24. CREININ MD, VITTINGHOFF E, KEDER L, DARNEY PD, TILLER G: Methotrexate and misoprostol for early abortion: a multicenter trial. I. Safety and efficacy. Contraception (1997) 56:169-174.
25. CREININ MD, VITTINGHOFF E: Methotrexate and misoprostol versus misoprostol alone for early abortion: a randomized controlled clinical trial. JAMA (1994) 272:1190-1195.
26. BUGALHO A, FAUNDES A, JAMISSE L et al.: Evaluation of effectiveness of vaginal misoprostol to induce first trimester abortion. Contraception (1996) 53:243-246.
27. KOOPERSMITH TB, MISHELL DR: The use of misoprostol for termination of early pregnancy. Contraception (1996) 53:237-242.
28. JAIN JK, DUTTON C, HARWOOD B, MECKSTROTH KR, MISHELL DR Jr: A prospective, randomised double blind placebo controlled trial comparing mifepristone and vaginal misoprostol and vaginal misoprostol alone for elective termination of early pregnancy. Hum. Reprod. (2002) 17:1477-1482.
29. HO PC, NGAI SW, LIU KL, WONG GC, LEE SW: Vaginal misoprostol compared with oral misoprostol in termination of second trimester pregnancy. Obstet. Gynecol (1997) 5:735-738.
30. GEMZELL-DANIELSSON K, MARIONS L, RODRIGUEZ A et al: Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet. Gynecol. (1999) 93:275-280.
31. SINGH K, FONG YF, PRASAD RN, DONG F: Does an acidic medium enhance the efficacy of vaginal misoprostol for pre-abortion cervical priming. Hum. Reprod. (1999) 14(6):1635-1637.
32. TANG OS, SCHWEER H, SEYBERTH HW. LEE SW, HO PC: Pharmacokinetics of different routes of administration of misoprostol. Hum. Reprod. (2002) 17(2):332-336.
33. CREININ MD, CARBONELL JLL, SCHWARTZ JL, VARELA L, TANDA R: A randomised trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception (1999) 59:11-16.
34. BOONSTRA H, SONFIELD A: Rights without access: revisiting public funding of abortion for poor women. The Guttmacber Report on Public Policy (2000) 3:8-12.
35. HENSHAW SK, WALLISCH LS: The Medicaid cutoff and abortion services for the poor. Fam. Plan. Perspect. (1984) 16:170-180.
36. SCHAFF EA, STADALIUS LS, EISINGER SH, FRANKS P: Vaginal misoprostol administered at home after mifepristone (RU-486). J. Fam. Pract. (1997) 44:353-360.
37. HENSHAW SK: Abortion incidence and services in the United States, 1995-1996. Fam. Plan. Perspect. (1998) 30(6):263-287.
38. FJERSTAD M: Medical abortion update. In: Reproductive Health 2002, Syllabus. Association of Reproductive Health Professionals (Pub) Washington DC, USA. (2002):168-171.
39. LICHTENBERG ES, GRIMES DA, PAUL M: Abortion complications, prevention and management. In: A Clinician's Guide to Medical and Surgical Abortion. Paul M, Lichtenberg ES, Borgatta L, Grimes DA, Stubblefield PG (Eds), Churchill Livingstone Publishers, NY, USA (1999):197-216.
40. CREININ MD: Early medical abortion with mifepristone and other agents: overview and guidelines. National Abortion Federation, Washington DC, USA (2002).
41. CREININ MD: Randomized comparison of efficacy, acceptability and cost of medical versus surgical abortion. Contraception (2000) 62:117-124.
42. HENSHAW SK: Abortion services under National Health Insurance: the examples of England and France. Fam. Plan. Perspect. (1994) 26:87-89.
43. ELLERTON C, ELUL B, AMBARDEKAR S, WOOD L, CARROLL J, COYAJI K: Accuracy of assessment of pregnancy duration by women seeking early abortion. Lancet (2000) 355:877-881.
44. MEIER KJ, MCFARLANE DR. State family planning and abortion expenditures: their effect on public health. Am. J. Public Health (1994) 84:1468-1472.
45. CHAMIE M, HENSHAW SK: The costs and benefits of government expenditures for family planning programs. Fam. Plan. Perspect. (1981) 13:117-124.
46. Issues in Brief: abortion in context: United States and Worldwide. In: Sharing responsibility: women, society and abortion worldwide, The Alan Guttmacher Insitute, NY, USA (1999).
47. JONES RK, HENSHAW SK: Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. Perspect. Sex. Reproduct. Health (2002) 34:154-161.
48. BYGDEMAN M, GEMZELL-DANIELSSON K, MARIONS L: Medical termination of early pregnancy: the Swedish experience. J. Am. Med. Women's Assoc. (2000)55:195-197.
49. Facts in brief: induced abortion worldwide. The Alan Guttmacher Institute, NY, USA (2003).
50. JENSEN JT, ASTLEY SJ, MORGAN E, NICHOLS MD: Outcomes of suction curettage and mifepristone abortion in the United States. Contraception (199 1) 59:153-159.
51. HOWIE FL, HENSHAW RC, NAJI SA, RUSSELL IT, TEMPLETON AA: Medical abortion or vacuum aspiration? Two year follow up of a patient preference trial. Br. J. Obstet. Gynaecol. (1997) 104:829-833.
52. WIEBE ER, JANSSEN PJ: Time lost from work among women choosing medical or surgical abortions. Women's Health Issues (2000) 10:327-332.
53. BOONSTRA H: Mifepristone in the United States: Status and future. The Guttmacher Report on Public Policy (2002) 5:4-7.
54. SWAHN ML, BYGDEMAN M: The effect of the antiprogestin RU-486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br.J. Obstet. Gynaecol. (1988) 95:126-134.
55. SILVESTRE L, DUBOIS C, RENAULT M, REZVANI Y, BAULIEU EE, ULMANN A: Voluntary interruption of pregnancy with mifepristone (RU-486) and a prostaglandin analogue. A large scale French experience. N. Engl. J. Med. (1990) 322:645-648.
56. SLADE P, HEKE S, FLETCHER J, STEWART P: A comparison of medical and surgical termination of pregnancy: choice, emotional impact and satisfaction with care. Br. J. Obstet. Gynaecol. (1998) 105:1288-1295.
57. MACROW PJ: Political, economic and ethical aspects of use of medical abortifacients. Pharmacoeconomics (1994) 5:269-273.
58. LEE PR, STEWART FH: Failing to prevent unintended pregnancy is costly. Am. J. Public Health (1995) 85:479-480.
59. EVANS MI, GLEICHER E, FEINGOLD E, JOHNSON MP, SOKOL RJ: The fiscal impact of the medicaid abortion funding ban in Michigan. Obstet. Gynecol. (1993) 82:555-560.
60. HENSHAW RC, NAJI SA, RUSSELL IT, TEMPLETON AA: A prospective economic evaluation comparing medical abortion (using mifepristone and gemeprost) and surgical vacuum aspiration. Br. J. Fam. Plan. (1994) 20:64-68.
61. NORMAN JE, THONG KJ, BAIRD DT: Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet (1991) 338:1233-1237.
62. NGAI SW, TANG OS, CHAN YM, HO PC: Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. Hum. Reprod. (2000) 15(5):1159-1162.